Oncological outcome of unresectable lung metastases without extrapulmonary metastases in colorectal cancer

Table 1 The clinicopathological characteristics and survival time of all the unresectable pulmonary metastases patients

Characteristics	Number (%)	Median OS (mo)	95% CI	P value
Gender
Male	21 (30)	22	9.0-35.0	0.487
Female	49 (70)	19	10.8-27.1
Age (yr)
≤ 60	42 (60)	24	19.5-28.5	0.093
> 60	28 (40)	13	7.8-13.2
Location of primary lesion
Colon	23 (32.9)	22	6.8-37.2	0.957
Rectum	47 (67.1)	19	10.7-27.2
Stage of primary lesion
I	4 (5.7)	11	5.1-16.9	0.766
II	11 (15.7)	27	14.1-39.9
III	36 (51.4)	18	8.6-27.4
IV	19 (27.1)	22	11.7-32.3
Unilateral or bilateral
Unilateral	3 (4.3)	Not reached	Not reached	0.769
Bilateral	67 (95.7)	19	12.6-25.4
Synchronous or metachronous
Synchronous	19 (27.1)	22	11.5-32.5	0.693
Metachronous	51 (72.9)	18	11.0-24.9
Regimen of first-line treatment
FOLFOX	32 (45.7)	17	9.4-24.6	0.556
XELOX	12 (17.1)	24	18.5-29.5
FOLFIRI	26 (37.1)	17	8.0-26.0
First response assessment
PR	25 (35.7)	27	23.4-30.6	0.00001
SD	36 (51.4)	16	8.3-23.7
PD	9 (12.9)	8	5.2-10.8

FOLFOX: Fluorouracil/leucovorin plus oxaliplatin; XELOX: Capecitabine plus oxaliplatin; FOLFIRI: Fluorouracil/leucovorin plus irinotecan; PR: Partial response; SD: Stable disease; PD: Progressive disease.